MET overexpression and gene amplification in NSCLC: a clinical perspective
Lorenza Landi, Gabriele Minuti, Armida D'Incecco, Jessica Salvini, Federico CappuzzoMedical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, ItalyAbstract: The transmembrane tyrosine kinase mesenchymal-epidermal transition (MET) receptor and its ligand, hepatocyte grow...
Guardado en:
Autores principales: | Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/22c9f43c6aca43b68b29d128428afaee |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021) -
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Mikkel G. Terp, et al.
Publicado: (2021) -
MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas
por: Zheng Zhao, et al.
Publicado: (2021) -
MET targeted therapy for lung cancer: clinical development and future directions
por: Feng Y, et al.
Publicado: (2012) -
Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Jessica S. Donington, MD
Publicado: (2021)